FORADIL CERTIHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Dec 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FORADIL CERTIHALER is an inhaled powder formulation approved in 2006 by Novartis. The specific indication and mechanism of action are not documented in available data, but the inhalation route and powder form suggest a respiratory therapeutic application. This is a small-molecule product delivered via a dry powder inhaler device.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling potential contraction of commercial teams and shift toward retention-focused strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career opportunities on FORADIL CERTIHALER are extremely limited and contracting. Professionals currently on this team should anticipate restructuring and seek transition opportunities to growth-stage products or pipeline assets.
Brand ManagerField Sales Representative
Worked on FORADIL CERTIHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.